MedTrace Logo

G-CSF-Induced Bone Pain and Supportive Care Approaches

NCT07192770 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2026-02-20

No results posted yet for this study

Summary

This prospective observational study aims to evaluate bone pain and related symptoms in patients with solid tumors receiving granulocyte colony-stimulating factor (G-CSF) during chemotherapy. A total of 128 patients will be enrolled at Ankara Etlik City Hospital. Pain severity will be assessed using the Visual Analog Scale (VAS), and supportive care strategies such as analgesics and non-pharmacological approaches will be documented. Patient-reported outcomes, including quality of life, fatigue, anxiety, depression, and sleep quality, will also be evaluated before and one week after G-CSF administration. The findings are expected to provide practical insights into the management of G-CSF-induced bone pain and improve supportive care practices.

Conditions

Interventions

BIOLOGICAL

Granulocyte colony-stimulating factor (G-CSF)

Patients receive chemotherapy with prophylactic G-CSF (granulocyte colony-stimulating factor) as part of routine clinical care. Both short-acting (filgrastim) and long-acting formulations (pegfilgrastim, lipegfilgrastim) may be used according to standard oncology practice. The study does not assign the intervention but observes supportive care strategies and patient-reported outcomes related to G-CSF-induced bone pain.

OTHER

Supportive Care (Analgesic and Non-Pharmacological Strategies)

Supportive care strategies including analgesic use (NSAIDs, opioids, antihistamines) and non-pharmacological interventions (rest, exercise, local heat/cold, relaxation techniques) will be recorded as part of routine practice. The study does not randomize or assign supportive care but documents their use and association with bone pain outcomes.

Sponsors & Collaborators

  • Ankara Etlik City Hospital

    lead OTHER_GOV

Principal Investigators

  • Enes Yeşilbaş, MD · Etlik City Hospital Medical Oncology Department

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-27
Primary Completion
2026-02-19
Completion
2026-02-19

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07192770 on ClinicalTrials.gov